PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Negative revenue growth is a classic Benjamin Graham warning sign. While possibly cyclical, verify Market Share trends and Competitive Position.
8.54%
Cost of revenue up 5-10% suggests cost challenges. Benjamin Graham would check if revenue growth compensates.
-83.05%
Negative gross profit growth is a serious warning sign. Benjamin Graham would demand thorough analysis of pricing power and cost structure.
No Data
No Data available this quarter, please select a different quarter.
-18.94%
Negative R&D growth (spending reduction) needs careful analysis. Benjamin Graham would examine impact on competitive position.
28.45%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Negative operating expenses growth needs verification. Benjamin Graham would examine sustainability.
-7.93%
Negative total costs growth needs verification. Benjamin Graham would examine sustainability.
-100.00%
Negative interest expense growth needs verification. Benjamin Graham would examine debt reduction strategy.
8.54%
D&A growth 5-10% suggests significant asset additions. Howard Marks would investigate investment returns.
7.52%
EBITDA growth 4-8% suggests moderate improvement. Benjamin Graham would check quality of earnings.
No Data
No Data available this quarter, please select a different quarter.
7.21%
Operating income growth 4-8% suggests moderate improvement. Benjamin Graham would check quality of earnings.
No Data
No Data available this quarter, please select a different quarter.
-9.03%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
7.01%
Pre-tax income growth 4-8% suggests moderate improvement. Benjamin Graham would check quality of earnings.
No Data
No Data available this quarter, please select a different quarter.
-68.42%
Negative tax expense growth needs verification. Benjamin Graham would examine sustainability.
7.01%
Net income growth 4-8% suggests moderate improvement. Benjamin Graham would check quality of earnings.
No Data
No Data available this quarter, please select a different quarter.
8.82%
EPS growth 8-12% reflects healthy business expansion. Philip Fisher would verify competitive position.
8.82%
Diluted EPS growth 8-12% reflects healthy expansion. Philip Fisher would verify competitive position.
0.91%
Share increase 0-2% indicates slight dilution. Howard Marks would investigate necessity.
0.91%
Diluted share increase 0-2% indicates slight dilution. Howard Marks would investigate necessity.